A Gene-Based Aesthetics CompanyLearn More
Not an actual patient
Jeune Inc. is a biotechnology company leveraging a clinically validated gene-delivery platform to fundamentally address – and reverse – the biology of aging or photo-damaged skin.
Jeune was formed in April 2019 by Krystal Biotech to advance a portfolio of innovative treatments that address aesthetic skin conditions. Our product candidates are based on Krystal’s Skin TARgeted Delivery platform, or STAR-D platform. This skin-optimized gene delivery technology enables us to specifically target key cells in the skin for delivery of a desired effector (gene). In doing so, we aim to stimulate a patient’s own cells to produce the important structural proteins that normally decline over time as we age (intrinsic aging) and with photo-damage (extrinsic aging).Learn More
Changes in the amount and organization of important proteins, like collagen and elastin, are the primary factor in the appearance of aging or damaged skin.
Current treatments artificially address these changes by “freezing” the face or adding artificial volume. Jeune’s pipeline of innovative treatments are designed to directly address the biology of aging skin by stimulating a patient’s own cells to produce the proteins that keep skin looking younger and healthier.
Publications and Presentations
Krishnan et al., SID 2021
Friedman et al., ASDS 2020
aesthetic skin conditions
type III collagen
type I collagen
type III collagen + elastin
type IV collagen